Skip to content
Subscriber Only

Biotech Stocks Ready for More Covid-19 Results in First Quarter

  • Data is also expected from Sarepta on DMD gene therapy trial
  • Benchmark industry index has outperformed broader stock market
A healthcare worker prepares to administer a dose of the Pfizer-BioNTech Covid-19 vaccine.
A healthcare worker prepares to administer a dose of the Pfizer-BioNTech Covid-19 vaccine.Photographer: Eva Marie Uzcategui/Bloomberg

Potential approval of an Alzheimer’s medicine, new gene therapy data and more late-stage clinical trial results for Covid-19 vaccines will keep momentum up for biotech stocks in the next three months.

The benchmark Nasdaq Biotech Index has climbed 26% this year, compared with a 15% gain in the S&P 500 Index, pointing to no let-up in market-moving drug trial data even during the pandemic.